Hi, how can I assist you today?
The 19q12 Bladder Cancer GWAS Signal: 5808
PCTAIRE1 Phosphorylates p27 and Regulates 5795
Mycoplasma Hyorhinis Infection Promotes NF-kB–Dependent Migration of Gastric Cancer Cells 582
PCTAIRE1 Phosphorylates p27 and Regulates Mitosis in Cancer Cells 5795

PREVENTION AND EPIDEMIOLOGY

THE THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

Copper Signaling Axis as a Target for Prostate Cancer Therapeutics 5819
Metabolic Vulnerabilities in Endometrial Cancer 5832
5846  In Vivo Localization of 90Y and 177Lu Radioimmunoconjugates Using Cerenkov Luminescence Imaging in a Disseminated Murine Leukemia Model
Ethan R. Balkin, Aimee Kenoyer, Johnnie J. Orozco, Alexandra Hernandez, Maziar Shadman, Darrell R. Fisher, Damian J. Green, Mark D. Hylarides, Oliver W. Press, D. Scott Wilbur, and John M. Pagel
Précis: Results demonstrate the feasibility of using a novel noninvasive imaging technique called Cerenkov Light Imaging (CLI) to optimize the use of radioimmunoconjugates used to treat aggressive leukemias.

5855  SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
Shaomeng Wang, Wei Sun, Yujun Zhao, Donna McEachern, Isabelle Meaux, Cédric Barrière, Jeanne A. Stuckey, Jennifer L. Meagher, Longchuan Bai, Liu Liu, Cassandra Gianna Hoffman-Luca, Jianfeng Lu, Sanjeev Shangary, Shanghui Yu, Denizil Bernard, Angelo Aguilar, Odette Dos-Santos, Laurent Besret, Stéphane Guerif, Pascal Pannier, Dimitri Gorge-Bernat, and Laurent Debussche
Précis: Despite the risk of applying a selection for p53 mutations that escape MDM2 control, blocking MDM2-p53 protein–protein interaction has long been considered by many to offer an attractive cancer therapeutic strategy, a position strongly supported by the findings of this preclinical study.

5866  Dsh Homolog DVL3 Mediates Resistance to IGFIR Inhibition by Regulating IGF-RAS Signaling
Shan Gao, Ilirjana Bajrami, Clare Verrill, Asha Kigoi, Djamila Ouaret, Tamara Aleksic, Ruth Asher, Cheng Han, Paul Allen, Deborah Bailey, Stephan Feller, Takeshi Kashima, Nicholas Athanasou, Jean-Yves Blay, Sandra Schmitz, Jean-Pascal Machiels, Nav Upile, Terry M. Jones, George Thalmann, Shazad Q. Ashraf, Jennifer L. Wilding, Walter F. Bodmer, Mark R. Middleton, Alan Ashworth, Christopher J. Lord, and Valentine M. Macaulay
Précis: This mechanistic study is important because it addresses the lack of predictive biomarkers for stratifying and recruiting cancer patients who might benefit from IGF-1 inhibitors, a key gap in their clinical development as cancer drugs.

5878  AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Catherine Wilson, Xiaofen Ye, Thinh Pham, Eva Lin, Sara Chan, Erin McNamara, Richard M. Neve, Lisa Belmont, Hartmut Koeppen, Robert L. Yauch, Avi Ashkenazi, and Jeff Settleman
Précis: These findings challenge a purported role for AXL in drug resistance while offering a novel rationale to combine AXL-targeting drugs with antimitotic agents to eradicate invasive cancers.

TUMOR AND STEM CELL BIOLOGY

5891  β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations
Sohei Nakayama, Natasha Ng, Julian Carretero, Robert Welner, Yuichiro Hayashi, Mihoko Yamamoto, Alistair J. Tan, Norihiro Yamaguchi, Hiroyuki Yasuda, Danan Li, Kenzo Soejima, Ross A. Soo, Daniel B. Costa, Kwok-Kin-Kung, and Susumu S. Kobayashi
Précis: Drug resistance to EGFR receptor antagonists in lung cancer may be mediated in part by activation of the β-catenin pathway, reinforcing its importance as an oncogenic driver in this setting.

5903  MYC Activates Stem-like Cell Potential in Hepatocarcinoma by a p53-Dependent Mechanism
Hirofumi Akita, Jens U. Marquardt, Marian E. Durkin, Mitsuteru Kitade, Daekwan Seo, Elizabeth A. Conner, Jesper B. Andersen, Valentina M. Factor, and Snorri S. Thorgeirsson
Précis: Cancer stem-like cell populations in liver cancer appear to be expanded under conditions in which MYC is activated and p53 is downregulated, with potential implications for understanding etiology, progression, and treatment in this disease.

5914  Zfx Facilitates Tumorigenesis Caused by Activation of the Hedgehog Pathway
Colin J. Palmer, Jose M. Galan-Caridad, Stuart P. Weisberg, Liang Lei, Jose M. Esquilin, Gist F. Croft, Brandon Wainwright, Peter Canoll, David M. Owens, and Boris Reizis
Précis: This preclinical genetic study identifies new candidate targets for the control of tumors driven by the Hedgehog pathway, the aberrant activation of which has been implicated widely in many types of human solid tumors.
SIRT6 Promotes COX-2 Expression and Acts as an Oncogene in Skin Cancer
Mei Ming, Weinong Han, Baozhong Zhao, Nagalingam R. Sundaresan, Chu-Xia Deng, Mahesh P. Gupta, and Yu-Ying He

Précis: This study challenges an existing view of the Sir2-related protein SIRT6 as a tumor suppressor, finding instead in a genetically deficient mouse that it functions as an oncogene in the skin epidermis.

ABOUT THE COVER
The AXL receptor tyrosine kinase has been implicated as a cellular signaling protein that is specifically upregulated in the context of the epithelial-to-mesenchymal transformation seen in some epithelial cancers and the emergence of acquired drug resistance. Among the tumor types in which a mesenchymal, largely drug-refractory phenotype appears to be prevalent is triple-negative breast cancer (TNBC). This immunohistological image illustrates the expression of AXL in a TNBC tumor specimen, revealing punctate cytoplasmic staining of AXL in tumor cells as well as focal vascular staining. For details, see article by Wilson and colleagues on page 5878.